571
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

, , , , , , , , ORCID Icon, , , , , ORCID Icon, , , , , & show all
Pages 473-477 | Received 13 Jul 2022, Accepted 03 Nov 2022, Published online: 14 Dec 2022
 

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work supported by National Institutes of Health/National Cancer Institute Grant Awards U10CA180888, U10CA180819, U10CA180821, U10CA180863, UG1CA233198, UG1CA233328, UG1CA189821, UG1CA233339, P30CA076292, UG1CA233193, and UG1CA189830. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.